Drug Profile
Research programme: caveolin modulators - E and B Technologies
Alternative Names: CVX-001Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator E and B Technologies
- Class Anti-inflammatories
- Mechanism of Action Membrane protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Uveitis
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Uveitis in USA (unspecified route)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Uveitis in USA
- 11 Aug 2016 Preclinical trials in Uveitis in USA (unspecified route)